Passage Bio

PASG · NASDAQ

$3.60+$0.02 (+0.56%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.58

About PASG

Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 24 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Employees: 24
Headquarters: PHILADELPHIA, Pennsylvania
Listed: Feb 28, 2020
Sector: Health Care
Industry: Biotechnology
Website: passagebio.com

Leadership

Passage Bio executives
Name	Title	Since	Age
Maxine Gowen	—	2021	67
William Chou	—	2022	52
Kathleen Borthwick	—	—	49
Edgar Cale	—	—	61
Athena Countouriotis	—	—	53
Sandip Kapadia	—	—	55
Thomas Kassberg	—	—	64
Derrell Porter	—	—	54
Dolan Sondhi	—	—	54

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Passage Bio suppliers and customers
Company	Relationship	Country	Correlation
Catalent CTLT	Supplier and customer	US	0.62
Trustees of the University of Pennsylvania	Supplier and customer	US	—

Similar companies

Companies in the same industry as Passage Bio

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.